Samsung Bioepis Initiates Phase 3 Clinical Trial for Proposed Pembrolizumab Biosimilar

The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.

Related Keywords

Ilsun Hong ,Gallaghera Samsung Bioepis ,Samsung Bioepis ,Keytruda Biosimilar ,Keytruda Pembrolizumab ,Samsung Bioepis Co Ltd ,Product Evaluation Team Leader Of Samsung Bioepis ,Product Evaluation Team Leader ,European Union Sourced ,United States Sourced ,Immunogenicity Between ,Bioepis Initiates Phase ,Proposed Biosimilar ,Proposed Keytruda ,